Could a simple hormone shot improve IVF live birth rates?
NCT ID NCT04064840
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding a hormone drug called Decapeptyl to standard IVF treatments can increase the number of live births. About 784 women under 43 with subfertility will receive either the drug or a placebo during egg retrieval and embryo transfer. The goal is to see if this approach leads to more successful pregnancies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Decapeptyl (gonadotropin-releasing hormone agonist)
- What this could lead to
- If successful, this could offer a simple drug adjustment to improve the chance of a live birth in IVF and frozen embryo transfers.
- What could go wrong
- This is a single-center trial, and results may not apply to all fertility clinics or patient groups. The drug may cause side effects like ovarian hyperstimulation or hormone imbalances.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SUBFERTILITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Department of Obstetrics and Gynaecology
RECRUITINGHong Kong, Hong Kong, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.